Introduction Given the increased infectious risk associated with biologics, particularly with
TNFα inhibitors, concerns were raised over the safety of these agents in relation to SARS …

Introduction Psoriasis has not been directly linked to a poor prognosis for COVID-19, yet
immunomodulatory agents used for its management may lead to increased vulnerability to …

Immunocompromised individuals, primarily attributable to using immunosuppressants, face
heightened COVID-19 risks. Despite the proven efficacy of COVID-19 vaccines, their impact …

Background mRNA-based COVID-19 vaccines have short-and long-term efficacy in healthy
individuals, but their efficacy in patients with psoriasis receiving immunomodulatory therapy …

To the Editor Ongoing COVID-19 infections and vaccinations necessitate understanding of
immunomodulatory agents in patients with immune-mediated diseases. Given the …

Since the outbreak of the COVID-19 pandemic in December 2019, scientists worldwide have
been looking for a way to control this global threat. One of the most successful and practical …

Background The rate of seroconversion after COVID-19 vaccination in patients with
moderate to severe psoriasis requiring systemic treatment is poorly understood. Objectives …

To the Editor, Vaccination during the COVID-19 pandemic was the most effective way to
prevent the SARS-COV-2 spreading and to reduce its morbidity/mortality. 1 In order to …

Biologicals or biologics, are 'large'molecules in sharp contrast to the 'small'molecules
represented by traditional drugs used. Biologics are currently used in several therapy areas …